Recombinant glucocerebrosidase (imiglucerase) as a therapy for gaucher disease

BioDrugs

Volumn 24, Issue 1, 2010, Pages 41-47

  Pastores, Gregory M ^a  

^a NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALGLUCERASE; ANTIHISTAMINIC AGENT; GLUCOSYLCERAMIDE; IMIGLUCERASE; IMIGLUCERASE I 123; PRGCR; RADIOISOTOPE; RECOMBINANT ENZYME; RECOMBINANT GLUCOCEREBROSIDASE; UNCLASSIFIED DRUG; VELAGLUCERASE ALFA;

AUTOIMMUNE HEPATITIS; BONE DENSITY; CENTRAL NERVOUS SYSTEM; CLINICAL FEATURE; CLINICAL TRIAL; DRUG COST; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG FORMULATION; DRUG HALF LIFE; DRUG INFUSION; DRUG MEGADOSE; DRUG SAFETY; DRUG TOLERABILITY; ENZYME REPLACEMENT; FEVER; FOOD AND DRUG ADMINISTRATION; GAUCHER DISEASE; HEALTH CARE COST; HUMAN; INFUSION SITE REACTION; LOW DRUG DOSE; PATIENT COMPLIANCE; PRIORITY JOURNAL; PRURITUS; REVIEW; RISK FACTOR; SYMPTOM; TREATMENT DURATION; TREATMENT INDICATION; TREATMENT RESPONSE; URTICARIA;

ANIMALS; GAUCHER DISEASE; GLUCOSYLCERAMIDASE; HUMANS; RECOMBINANT PROTEINS;

EID: 75149112725     PISSN: 11738804     EISSN: 1179190X     Source Type: Journal    
DOI: 10.2165/11318540-000000000-00000     Document Type: Review

References (57)

1. Charrow J. Enzyme replacement therapy for Gaucher disease. Expert Opin Biol Ther 2009; 9 (1): 121-131
2. Boven LA, van MeursM, Boot RG, et al. Gaucher cells demonstrate a distinct macrophage phenotype and resemble alternatively activated macrophages. Am J Clin Pathol 2004; 122 (3): 359-369
3. Rogaeva E, Hardy J. Gaucher and Parkinson diseases: unexpectedly related. Neurology 2008; 70 (24): 2272-2273
4. Weinreb NJ. Imiglucerase and its use for the treatment of Gaucher's disease. Expert Opin Pharmacother 2008; 9 (11): 1987-2000
5. Grabowski GA, Barton NW, Pastores G, et al. Enzyme therapy in type 1 Gaucher disease: comparative efficacy ofmannose-terminated glucocerebrosidase from natural and recombinant sources. Ann Intern Med 1995; 122 (1): 33-39
6. Grabowski GA. Delivery of lysosomal enzymes for therapeutic use: glucocerebrosidase as an example. Expert Opin Drug Deliv 2006; 3 (6): 771-782
7. Pastores GM, Giraldo P, Chérin P, et al. Goal-oriented therapy with miglustat in Gaucher disease. Curr Med Res Opin 2009; 25 (1): 23-37
8. Jmoudiak M, Futerman AH. Gaucher disease: pathological mechanisms and modern management. Br J Haematol 2005; 129 (2): 178-188
9. Reczek D, Schwake M, Schröder J, et al. LIMP-2 is a receptor for lysosomal mannose-6-phosphate-independent targeting of beta-glucocerebrosidase. Cell 2007; 131 (4): 770-783
10. Balreira A, Gaspar P, Caiola D, et al. A nonsense mutation in the LIMP-2 gene associated with progressive myoclonic epilepsy and nephrotic syndrome. Hum Mol Genet 2008; 17 (14): 2238-2243
11. Park JK, Orvisky E, Tayebi N, et al. Myoclonic epilepsy in Gaucher disease: genotype-phenotype insights from a rare patient subgroup. Pediatr Res 2003; 53 (3): 387-395
12. Taddei TH, Kacena KA, Yang M, et al. The underrecognized progressive nature of N370S Gaucher disease and assessment of cancer risk in 403 patients. Am J Hematol 2009; 84 (4): 208-214
13. Ron I, Horowitz M. ER retention and degradation as the molecular basis underlying Gaucher disease heterogeneity. Hum Mol Genet 2005; 14 (16): 2387-2398
14. Kacher Y, Futerman AH. Impaired IL-10 transcription and release in animal models of Gaucher disease macrophages. Blood Cells Mol Dis 2009; 43 (1): 134-137
15. Yoshino M, Watanabe Y, Tokunaga Y, et al. Roles of specific cytokines in bone remodeling and hematopoiesis in Gaucher disease. Pediatr Int 2007; 49 (6): 959-965
16. Aerts JM, van Breemen MJ, Bussink AP, et al. Biomarkers for lysosomal storage disorders: identification and application as exemplified by chitotriosidase in Gaucher disease. Acta Paediatr Suppl 2008; 97 (457): 7-14
17. van Breemen MJ, de Fost M, Voerman JS, et al. Increased plasma macrophage inflammatory protein (MIP)-1alpha and MIP-1beta levels in type 1 Gaucher disease. Biochim Biophys Acta 2007; 1772 (7): 788-796
18. Hein LK, Meikle PJ, Hopwood JJ, et al. Secondary sphingolipid accumulation in a macrophage model of Gaucher disease. Mol Genet Metab 2007; 92 (4): 336-345
19. Mistry PK, Wraight EP, Cox TM. Therapeutic delivery of proteins to macrophages: implications for treatment of Gaucher's disease. Lancet 1996; 348 (9041): 1555-1559
20. Zimran A, Loveday K, Fratazzi C, et al. A pharmacokinetic analysis of a novel enzyme replacement therapy with gene-activated human glucocerebrosidase (GA-GCB) in patients with type 1Gaucher disease. Blood Cells MolDis 2007; 39 (1): 115-118
21. Aviezer D, Brill-Almon E, Shaaltiel Y, et al. A plant-derived recombinant human glucocerebrosidase enzyme: a preclinical and phase I investigation. PLoS ONE 2009; 4 (3): e4792
22. Zimran A, Elstein D, Levy-Lahad E, et al. Replacement therapy with imiglucerase for type 1 Gaucher's disease. Lancet 1995; 345 (8963): 1479-1480
23. Sims KB, Pastores GM, Weinreb NJ, et al. Improvement of bone disease by imiglucerase (Cerezyme) therapy in patients with skeletal manifestations of type 1 Gaucher disease: results of a 48-month longitudinal cohort study. Clin Genet 2008; 73 (5): 430-440
24. Kishnani PS, DiRocco M, Kaplan P, et al. A randomized trial comparing the efficacy and safety of imiglucerase (Cerezyme) infusions every 4 weeks versus every 2 weeks in the maintenance therapy of adult patients with Gaucher disease type 1. Mol Genet Metab 2009; 96 (4): 164-170
25. Weinreb NJ, Charrow J, Andersson HC, et al. Effectiveness of enzyme replacement therapy in 1028 patients with type 1 Gaucher disease after 2 to 5 years of treatment: a report from the Gaucher Registry. Am J Med 2002; 113 (2): 112-119
26. Weinreb N, Taylor J, Cox T, et al. A benchmark analysis of the achievement of therapeutic goals for type 1 Gaucher disease patients treated with imiglucerase. Am J Hematol 2008; 83 (12): 890-895
27. Wenstrup RJ, Kacena KA, Kaplan P, et al. Effect of enzyme replacement therapy with imiglucerase on BMD in type 1 Gaucher disease. J Bone Miner Res 2007; 22 (1): 119-126
28. Pastores GM, WeinrebNJ, Aerts H, et al. Therapeutic goals in the treatment of Gaucher disease. Semin Hematol 2004; 41 (4 Suppl. 5): 4-14
29. Charrow J, Dulisse B, Grabowski GA, et al. The effect of enzyme replacement therapy on bone crisis and bone pain in patients with type 1 Gaucher disease. Clin Genet 2007; 71 (3): 205-211
30. Wenstrup RJ, Bailey L, Grabowski GA, et al. Gaucher disease: alendronate disodium improves bone mineral density in adults receiving enzyme therapy. Blood 2004; 104 (5): 1253-1257
31. AnderssonH,Kaplan P, Kacena K, et al. Eight-year clinical outcomes of longterm enzyme replacement therapy for 884 children with Gaucher disease type 1. Pediatrics 2008; 122 (6): 1182-1190
32. Kaplan P, Mazur A, Manor O, et al. Acceleration of retarded growth in children with Gaucher disease after treatment with alglucerase. J Pediatr 1996; 129 (1): 149-153
33. Weinreb N, Barranger J, Packman S, et al. Imiglucerase (Cerezyme) improves quality of life in patients with skeletal manifestations of Gaucher disease. Clin Genet 2007; 71 (6): 576-588
34. Zimran A, Hadas-Halpern I, Zevin S, et al. Low-dose high-frequency enzyme replacement therapy for very young children with severe Gaucher disease. Br J Haematol 1993; 85 (4): 783-786 (Pubitemid 24003596)
35. Hollak CE, Aerts JM, Goudsmit R, et al. Individualised low-dose alglucerase therapy for type 1 Gaucher's disease. Lancet 1995; 345 (8963): 1474-1478
36. Weinreb NJ, Deegan P, Kacena KA, et al. Life expectancy in Gaucher disease type 1. Am J Hematol 2008; 83 (12): 896-900
37. Starzl TE, Demetris AJ, Trucco M, et al. Chimerism after liver transplantation for type IV glycogen storage disease and type 1 Gaucher's disease. N Engl J Med 1993; 328 (11): 745-749
38. Smanik EJ, Tavill AS, Jacobs GH, et al. Orthotopic liver transplantation in two adults with Niemann-Pick and Gaucher's diseases: implications for the treatment of inherited metabolic disease. Hepatology 1993; 17 (1): 42-49
39. Elstein D, Abrahamov A, Zimran A. Ethical considerations for enzyme replacement therapy in neuronopathic Gaucher disease. Clin Genet 1998; 54 (3): 179-184
40. Davies EH, Erikson A, Collin-Histed T, et al. Outcome of type III Gaucher disease on enzyme replacement therapy: review of 55 cases. J Inherit Metab Dis 2007; 30 (6): 935-993
41. Ringdén O, Groth CG, Erikson A, et al. Ten years' experience of bone marrow transplantation for Gaucher disease. Transplantation 1995; 59 (6): 864-870
42. Damiano AM, Pastores GM, Ware Jr JE. The health-related quality of life of adults with Gaucher's disease receiving enzyme replacement therapy: results from a retrospective study. Qual Life Res 1998; 7 (5): 373-386
43. de Fost M, Hollak CE, Groener JE, et al. Superior effects of high-dose enzyme replacement therapy in type 1 Gaucher disease on bone marrow involvement and chitotriosidase levels: a 2-center retrospective analysis. Blood 2006; 108 (3): 830-835
44. Pastores GM, Barnett NL. Current and emerging therapies for the lysosomal storage disorders. Expert Opin Emerg Drugs 2005; 10 (4): 891-902
45. Starzyk K, Richards S, Yee J, et al. The long-term international safety experience of imiglucerase therapy forGaucher disease. Mol Genet Metab 2007; 90 (2): 157-163
46. Zimran A, Morris E, Mengel E, et al. The female Gaucher patient: the impact of enzyme replacement therapy around key reproductive events (menstruation, pregnancy and menopause). Blood Cells Mol Dis 2009 Nov-Dec; 43 (3): 264-288
47. Connock M, Burls A, Frew E, et al. The clinical effectiveness and costeffectiveness of enzyme replacement therapy for Gaucher's disease: a systematic review. Health Technol Assess 2006; 10 (24): iii-iv, ix-136
48. Clarke JT, Amato D, Deber RB. Managing public payment for high-cost, highbenefit treatment: enzyme replacement therapy for Gaucher's disease in Ontario. CMAJ 2001; 165 (5): 595-596
49. Zimran A, Elstein D. No justification for very high-dose enzyme therapy for patients with type III Gaucher disease. J Inherit Metab Dis 2007; 30 (6): 843-844
50. Grabowski GA, Kacena K, Cole JA, et al. Dose-response relationships for enzyme replacement therapy with imiglucerase/alglucerase in patients with Gaucher disease type 1. Genet Med 2009; 11 (2): 92-100
51. Sidransky E, Pastores GM, Mori M. Dosing enzyme replacement therapy for Gaucher disease: older, but are we wiser? Genet Med 2009; 11 (2): 90-91
52. Elstein D, Abrahamov A, Hadas-Halpern I, et al. Withdrawal of enzyme replacement therapy in Gaucher's disease. Br J Haematol 2000; 110 (2): 488-492
53. McEachern KA, Fung J, Komarnitsky S, et al. A specific and potent inhibitor of glucosylceramide synthase for substrate inhibition therapy of Gaucher disease. Mol Genet Metab 2007; 91 (3): 259-267
54. Steet R, Chung S, LeeWS, et al. Selective action of the iminosugar isofagomine, a pharmacological chaperone for mutant forms of acid-beta-glucosidase. Biochem Pharmacol 2007; 73 (9): 1376-1383
55. McEachern KA, Nietupski JB, Chuang WL, et al. AAV8-mediated expression of glucocerebrosidase ameliorates the storage pathology in the visceral organs of a mouse model of Gaucher disease. J Gene Med 2006; 8 (6): 719-729
56. van Breemen MJ, de Fost M, Maas M, et al. Different dose-dependent correction of MIP-1beta and chitotriosidase during initial enzyme replacement therapy. J Inherit Metab Dis 2009; 32 (2): 274-279
57. Ailworth E, Weisman R. 'Virus shuts Genzyme plant, holds up drugs for 8000'. The Boston Globe. 2009 Jun 17 [online]. Available from URL: http://www. boston.com/business/healthcare/articles/2009/06/17/genzyme-temporarily- halts-production-on-2-key-drugs/ [Accessed 2009 Sep 10]